John Schmid

John Schmid has more than 35 years of financial and senior leadership experience in the biotechnology industry. He currently serves as a member of the boards of directors of AnaptysBio, Inc. (ANAB), Bright Peak Therapeutics, Design Therapeutics (DSGN), First Tracks Biotherapeutics (TRAX), and Helix Acquisition Corp. III (HLXC). Mr. Schmid also served as a member of the boards of directors of Poseida Therapeutics Inc., Xeris Pharmaceuticals, and Neos Therapeutics. Previously, Mr. Schmid served as chief financial officer of Auspex Pharmaceuticals, Inc. until its sale to Teva Pharmaceutical Industries Ltd. Prior to that, Mr. Schmid co-founded Trius Therapeutics where he served as the chief financial officer prior to its acquisition by Cubist Pharmaceuticals, Inc. Earlier in his career, Mr. Schmid served as the chief financial officer of GeneFormatics, Inc. and Endonetics Inc. Mr. Schmid received a B.A. in Economics from Wesleyan University and an M.B.A. from the University of San Diego.